Artificial Pancreas Project
Larry Fox, Principal Investigator
Nelly Mauras, Co-Investigator
Funding: Juvenile Diabetes Research Foundation
The use of continuous glucose sensor (CGS) technology is now a reality and offers the promise to potentially revolutionize diabetes care. In this large multicenter trial we will recruit 50 children with T1 diabetes and randomize them to use CGS or no CGS for 6 months, followed by CGS use by all for another 6 months. We hope to see whether the use if CGS can lower hemoglobin 1C and improve the quality of life of these children.
Safety & Efficacy of Exubera (Inhaled Insulin) Compared with Subcutaneous Human Insulin Therapy in Children & Adolescents Ages 6-17 Years with Type 1 Diabetes Mellitus: a 12-month, Outpatient Randomized, Open-label, Parallel-group Comparative Trial
Larry Fox, Principal Investigator
Nelly Mauras, Co-Investigator
Funding: Pfizer
This study focuses on the safety and efficacy of inhaled insulin in children with type 1 diabetes.
Amino-Terminal Propeptide of C-Type Natriuretic Peptide (NT-proCNP) levels in Healthy Children
Robert Olney, Prinicipal Investigator
Funding: Quest Diagnostics, Inc. and Nemours Research Programs
C-type natriuretic peptide (CNP) is an autocrine regulator of longitudinal growth. An amino-terminal propeptide (NT-proCNP) of CNP has recently been found and levels of NT-proCNP correlate remarkably well with growth velocity in lambs. This is a study of NT-proCNP levels in normal children to demonstrate that this peptide is a biomarker of normal growth and to define it’s reference range. Growth may be the single most important index of a child’s health, yet we have no means of measuring it at a single point in time. The determination of growth velocity is an important parameter in the evaluation of both normal children and children with chronic diseases. A biomarker of growth will allow clinicians to evaluate growth velocity at a single time point, dramatically reducing the time needed to properly evaluate and initiate therapy in patients presenting with short stature or to evaluate children at risk for growth impairment due to chronic disease. Growth is a barometer of childhood health and many diseases first present with a slow down of growth. NT-proCNP, viewed in the light of a validated reference range, may ultimately prove to be a screening tool to assess the general health of a child.